https://pittplusme.org/study/1245
HCC-18-006 – Ovarian Cancer Study
We're sorry. This study is closed and no longer recruiting participants.
STUDY BASICS
Have you been diagnosed with ovarian cancer that has come back after your previous treatment? If so, you may be eligible to participate in a study to help investigators evaluate the safety of a new anticancer drug, called ribociclib (LEE011). Involves receiving the study drug along with chemotherapy for 24 weeks. You will then receive the study drug by itself (maintenance dose).
IRB: STUDY19030437
- HCC 18-006, Phase I Trial of Ribociclib (Ribociclib (LEE011)) with Platinum-based Chemotherapy in Recurrent Platinum Sensitive Ovarian Cancer
AGE:
18 and up
SEX:
Female
LOCATION:
Magee-Women’s Hospital of UPMC
COMPENSATION:
NONE
SHARE STUDY
